pediatricjournalАрхив педиатрии и детской хирургииArchives of Pediatrics and Pediatric Surgery2949-46643033-6783НИКИ детства Минздрава Московской области10.31146/2949-4664-apps-2-4-35-42pediatricjournal-120Research ArticleМИКРОБИОЛОГИЯMICROBIOLOGYДинамика антибиотикорезистентности в отделениях реанимации и интенсивной терапии детского многопрофильного стационара г. ТомскаDynamics of antibiotic resistance in the intensive care and resuscitation departments of the children’s multidisciplinary hospital in Tomskhttps://orcid.org/0000-0002-3043-8674ЛошковаЕ. В.LoshkovaE. V.loshkova@rambler.ruhttps://orcid.org/0009-0008-7135-7361БудкинА. В.BudkinA. V.noemail@neicon.ruhttps://orcid.org/0000-0003-0596-635XСолнышкоА. Л.SolnyshkoA. L.noemail@neicon.ruhttps://orcid.org/0000-0002-3281-803XРафиковаЮ. С.RafikovaYu. S.noemail@neicon.ruhttps://orcid.org/0000-0003-3241-282XТерентьеваА. А.TerentyevaA. A.noemail@neicon.ruhttps://orcid.org/0000-0001-5792-2012ЯнкинаГ. Н.YankinaG. N.noemail@neicon.ruhttps://orcid.org/0000-0002-2133-665XЖелевВ. А.ZhelevV. A.noemail@neicon.ruhttps://orcid.org/0000-0003-4439-151XМихалевЕ. В.MikhalevE. V.noemail@neicon.ruhttps://orcid.org/0000-0003-2048-1852ЛюлькаТ. С.LyulkaT. S.noemail@neicon.ruhttps://orcid.org/0000-0002-0747-5952ДорошенкоИ. В.DoroshenkoI. V.noemail@neicon.ruБыковаЮ. И.BykovaY. I.noemail@neicon.ruhttps://orcid.org/0009-0004-6162-1190БалакиреваА. И.BalakirevaA. I.noemail@neicon.ruФедеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации; ОГАУЗ «Детская городская больница № 1»; Федеральное государственное бюджетное научное учреждение «Медико-генетический научный центр имени академика Н.П. Бочкова»Siberian state medical University; Children’s City Hospital no 1”; Research Center for Medical GeneticsОГКУЗ «Областной дом ребенка»Regional Children’s HomeФедеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации; ОГАУЗ «Детская городская больница № 1»Siberian state medical University; Children’s City Hospital no 1”Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования «Сибирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииSiberian state medical UniversityФедеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской ФедерацииSt. Petersburg State Pediatric Medical UniversityФГАОУ ВО «Белгородский государственный национальный исследовательский университет»Belgorod National Research University202418122024243542Copyright © Лошкова Е.В., Будкин А.В., Солнышко А.Л., Рафикова Ю.С., Терентьева А.А., Янкина Г.Н., Желев В.А., Михалев Е.В., Люлька Т.С., Дорошенко И.В., Быкова Ю.И., Балакирева А.И., 20242024Лошкова Е.В., Будкин А.В., Солнышко А.Л., Рафикова Ю.С., Терентьева А.А., Янкина Г.Н., Желев В.А., Михалев Е.В., Люлька Т.С., Дорошенко И.В., Быкова Ю.И., Балакирева А.И.Loshkova E.V., Budkin A.V., Solnyshko A.L., Rafikova Y.S., Terentyeva A.A., Yankina G.N., Zhelev V.A., Mikhalev E.V., Lyulka T.S., Doroshenko I.V., Bykova Y.I., Balakireva A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nikid.ru/jour/article/view/120

В настоящей статье проанализирована динамика антибиотикорезистентности Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, колонизирующих различные локусы пациентов, находящихся в тяжелом состоянии и / или имеющих паллиативный статус. Показано увеличение резистентности к антибактериальным препаратам, использующимся как в качестве первой линии терапии, так и в качестве резервных антибиотиков. Ситуация с увеличением антимикробной резистентности требует формулировки микробиологического диагноза при выписке пациента из стационара, микробиологического мониторинга мультирезистентных патогенов после выписки из стационара, в том числе, среди пациентов, имеющих паллиативный статус.

This article analyzes the dynamics of antibiotic resistance of Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, colonizing various loci of patients in serious condition and / or with palliative status. An increase in resistance to antibacterial drugs used both as first-line therapy and as reserve antibiotics is shown. The situation with an increase in antimicrobial resistance requires the formulation of a microbiological diagnosis when discharging a patient from the hospital, microbiological monitoring of multiresistant pathogens after discharge from the hospital, including among patients with palliative status.

воспалениеноворожденные детимультирезистентные патогеныантибиотикорезистентностьKlebsiella pneumoniaeEscherichia coliPseudomonas aeruginosainflammationnewbornsmultiresistant pathogensantibiotic resistanceKlebsiella pneumoniaeEscherichia coliPseudomonas aeruginosaReferencesEndale H., Mathewos M., Abdeta D. Potential Causes of Spread of Antimicrobial Resistance and Preventive Measures in One Health Perspective-A Review. Infect Drug Resist. 2023 Dec 8;16:7515-7545. doi: 10.2147/IDR.S428837.Endale H., Mathewos M., Abdeta D. Potential Causes of Spread of Antimicrobial Resistance and Preventive Measures in One Health Perspective-A Review. Infect Drug Resist. 2023 Dec 8;16:7515-7545. doi: 10.2147/IDR.S428837.Yin L., Wu N., Yan G. et al. Carbapenem-resistant gram-negative bacterial prevention practice in nosocomial infection and molecular epidemiological characteristics in a pediatric intensive care unit. Heliyon. 2023 Aug 6;9(8): e18969. doi: 10.1016/j.heliyon.2023.e18969.Yin L., Wu N., Yan G. et al. Carbapenem-resistant gram-negative bacterial prevention practice in nosocomial infection and molecular epidemiological characteristics in a pediatric intensive care unit. Heliyon. 2023 Aug 6;9(8): e18969. doi: 10.1016/j.heliyon.2023.e18969.Guo Y., Han R., Jiang B., Ding L., Yang F., Zheng B., Yang Y., Wu S., Yin D., Zhu D., Hu F.; China Antimicrobial Surveillance Network (CHINET) Study Group. In Vitro Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019. Microbiol Spectr. 2022 Aug 31;10(4): e0185422. doi: 10.1128/spectrum.01854-22.Guo Y., Han R., Jiang B., Ding L., Yang F., Zheng B., Yang Y., Wu S., Yin D., Zhu D., Hu F.; China Antimicrobial Surveillance Network (CHINET) Study Group. In Vitro Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019. Microbiol Spectr. 2022 Aug 31;10(4): e0185422. doi: 10.1128/spectrum.01854-22.Sader H.S., Mendes R.E., Duncan L.R., Carvalhaes C.G., Castanheria M. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19). J Antimicrob Chemother. 2022 Sep 30;77(10):2642-2649. doi: 10.1093/jac/dkac233.Sader H.S., Mendes R.E., Duncan L.R., Carvalhaes C.G., Castanheria M. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19). J Antimicrob Chemother. 2022 Sep 30;77(10):2642-2649. doi: 10.1093/jac/dkac233.Scoffone V.C., Barbieri G., Irudal S., Trespidi G., Buroni S. New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis. Antibiotics (Basel). 2024 Jan 11;13(1):71. doi: 10.3390/antibiotics13010071.Scoffone V.C., Barbieri G., Irudal S., Trespidi G., Buroni S. New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis. Antibiotics (Basel). 2024 Jan 11;13(1):71. doi: 10.3390/antibiotics13010071.Marner M., Kolberg L., Horst J. et al. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients. Microbiol Spectr. 2023 Feb 14;11(1): e0443722. doi: 10.1128/spectrum.04437-22.Marner M., Kolberg L., Horst J. et al. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients. Microbiol Spectr. 2023 Feb 14;11(1): e0443722. doi: 10.1128/spectrum.04437-22.Sid Ahmed M.A., Hamid J.M., Hassan A.M.M., Abu Jarir S., Bashir Ibrahim E., Abdel Hadi H. Phenotypic and Genotypic Characterization of Pan-Drug-Resistant Klebsiella pneumoniae Isolated in Qatar. Antibiotics (Basel). 2024 Mar 19;13(3):275. doi: 10.3390/antibiotics13030275.Sid Ahmed M.A., Hamid J.M., Hassan A.M.M., Abu Jarir S., Bashir Ibrahim E., Abdel Hadi H. Phenotypic and Genotypic Characterization of Pan-Drug-Resistant Klebsiella pneumoniae Isolated in Qatar. Antibiotics (Basel). 2024 Mar 19;13(3):275. doi: 10.3390/antibiotics13030275.Ding L., Shen S., Chen J., Tian Z., Shi Q., Han R., Guo Y., Hu F. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clin Microbiol Rev. 2023 Dec 20;36(4): e0000823. doi: 10.1128/cmr.00008-23.Ding L., Shen S., Chen J., Tian Z., Shi Q., Han R., Guo Y., Hu F. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clin Microbiol Rev. 2023 Dec 20;36(4): e0000823. doi: 10.1128/cmr.00008-23.Loshkova E.V., Solnyshko A.L., Lyamin A.V. et al. Chronic critical patient in pediatrics: microbiological “portrait” and problems of antibiotic resistance. Archives of Pediatrics and Pediatric Surgery. 2024;2(1):24-46. (In Russ.) doi: 10.31146/2949-4664-apps-2-1-24-46.@@ Лошкова Е.В., Солнышко А.Л., Лямин А.В. и др. Хронический критический пациент в педиатрии: микробиологический «портрет» дыхательной системы и проблемы антибиотикорезистентности. Архив педиатрии и детской хирургии. 2024;2(1):24-46. doi: 10.31146/2949-4664-apps-2-1-24-46.Loshkova E.V., Solnyshko A.L., Lyamin A.V. et al. Chronic critical patient in pediatrics: microbiological “portrait” and problems of antibiotic resistance. Archives of Pediatrics and Pediatric Surgery. 2024;2(1):24-46. (In Russ.) doi: 10.31146/2949-4664-apps-2-1-24-46.@@ Лошкова Е.В., Солнышко А.Л., Лямин А.В. и др. Хронический критический пациент в педиатрии: микробиологический «портрет» дыхательной системы и проблемы антибиотикорезистентности. Архив педиатрии и детской хирургии. 2024;2(1):24-46. doi: 10.31146/2949-4664-apps-2-1-24-46.De Boeck K. Cystic fibrosis in the year 2020: disease with a new face. Acta Paediatr. 2020; 109(5): 893-899. doi: 10.1111/apa.15155.De Boeck K. Cystic fibrosis in the year 2020: disease with a new face. Acta Paediatr. 2020; 109(5): 893-899. doi: 10.1111/apa.15155.[Clinical guidelines «Cystic fibrosis (mucoviscidosis)»]. 2023. (in Russ.) Available at: https://mukoviscidoz.orgdoc/%D0%9A%D0%A0372.pdf (Accessed: 05.05.2024)[Clinical guidelines «Cystic fibrosis (mucoviscidosis)»]. 2023. (in Russ.) Available at: https://mukoviscidoz.orgdoc/%D0%9A%D0%A0372.pdf (Accessed: 05.05.2024)Kondratyeva E.I., Avdeev S.N., Mizernitskiy Yu.L. et al. Primary ciliary dyskinesia: review of the draft clinical guidelines, 2022. PULMONOLOGIYA. 2022;32(4):517-538. (In Russ.) doi: 10.18093/0869-0189-2022-32-4-517-538.@@ Кондратьева Е.И., Авдеев С.Н., Мизерницкий Ю.Л. и др. Первичная цилиарная дискинезия: обзор проекта клинических рекомендаций 2022 года. Пульмонология. 2022;32(4):517-538. doi: 10.18093/0869-0189-2022-32-4-517-538.Kondratyeva E.I., Avdeev S.N., Mizernitskiy Yu.L. et al. Primary ciliary dyskinesia: review of the draft clinical guidelines, 2022. PULMONOLOGIYA. 2022;32(4):517-538. (In Russ.) doi: 10.18093/0869-0189-2022-32-4-517-538.@@ Кондратьева Е.И., Авдеев С.Н., Мизерницкий Ю.Л. и др. Первичная цилиарная дискинезия: обзор проекта клинических рекомендаций 2022 года. Пульмонология. 2022;32(4):517-538. doi: 10.18093/0869-0189-2022-32-4-517-538.Fan P., Fu P., Liu J., Wang C., Zhang X., Wang Y., Zhang Y., Zhu T., Zhang C., Lu G., Yan G.; China Paediatric Intensive Care Unit Pathogen Surveillance Network (CHIPS) Study Group; Members and affiliations of China Paediatric Intensive care Unit Pathogen Surveillance Network (CHIPS). Monitoring of Klebsiella pneumoniae Infection and Drug Resistance in 17 Pediatric Intensive Care Units in China from 2016 to 2022. Infect Drug Resist. 2024 Sep 23;17:4125-4136. doi: 10.2147/IDR.S475720.Fan P., Fu P., Liu J., Wang C., Zhang X., Wang Y., Zhang Y., Zhu T., Zhang C., Lu G., Yan G.; China Paediatric Intensive Care Unit Pathogen Surveillance Network (CHIPS) Study Group; Members and affiliations of China Paediatric Intensive care Unit Pathogen Surveillance Network (CHIPS). Monitoring of Klebsiella pneumoniae Infection and Drug Resistance in 17 Pediatric Intensive Care Units in China from 2016 to 2022. Infect Drug Resist. 2024 Sep 23;17:4125-4136. doi: 10.2147/IDR.S475720.Russell N.J., Stöhr W., Plakkal N.et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS). PLoS Med. 2023 Jun 8;20(6): e1004179. doi: 10.1371/journal.pmed.1004179.Russell N.J., Stöhr W., Plakkal N.et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS). PLoS Med. 2023 Jun 8;20(6): e1004179. doi: 10.1371/journal.pmed.1004179.China Antimicrobial Resistance Surveillance System. [Surveillance of bacterial resistance in children and newborns across China from 2014 to 2017]. Zhonghua Yi Xue Za Zhi. 2018 Oct 30;98(40):3279-3287. Chinese. doi: 10.3760/cma.j.issn.0376-2491.2018.40.013.China Antimicrobial Resistance Surveillance System. [Surveillance of bacterial resistance in children and newborns across China from 2014 to 2017]. Zhonghua Yi Xue Za Zhi. 2018 Oct 30;98(40):3279-3287. Chinese. doi: 10.3760/cma.j.issn.0376-2491.2018.40.013.Wang J., Zhang H., Yan J., Zhang T. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis. J Matern Fetal Neonatal Med. 2022 Mar;35(5):861-870. doi: 10.1080/14767058.2020.1732342.Wang J., Zhang H., Yan J., Zhang T. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis. J Matern Fetal Neonatal Med. 2022 Mar;35(5):861-870. doi: 10.1080/14767058.2020.1732342.Pinto Jimenez C.E., Keestra S., Tandon P., Cumming O., Pickering A.J., Moodley A., Chandler C.I.R. Biosecurity and water, sanitation, and hygiene (WASH) interventions in animal agricultural settings for reducing infection burden, antibiotic use, and antibiotic resistance: a One Health systematic review. Lancet Planet Health. 2023 May;7(5): e418-e434. doi: 10.1016/S2542-5196(23)00049-9.Pinto Jimenez C.E., Keestra S., Tandon P., Cumming O., Pickering A.J., Moodley A., Chandler C.I.R. Biosecurity and water, sanitation, and hygiene (WASH) interventions in animal agricultural settings for reducing infection burden, antibiotic use, and antibiotic resistance: a One Health systematic review. Lancet Planet Health. 2023 May;7(5): e418-e434. doi: 10.1016/S2542-5196(23)00049-9.Cui Q., Wang C., Wang Q., Qin J., Li M., Ding B., Shen Z. Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae. Emerg Infect Dis. 2023 Nov;29(11):2398-2400. doi: 10.3201/eid2911.230830.Cui Q., Wang C., Wang Q., Qin J., Li M., Ding B., Shen Z. Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae. Emerg Infect Dis. 2023 Nov;29(11):2398-2400. doi: 10.3201/eid2911.230830.Wang J., Zhang H., Yan J., Zhang T. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis. J Matern Fetal Neonatal Med. 2022 Mar;35(5):861-870. doi: 10.1080/14767058.2020.1732342.Wang J., Zhang H., Yan J., Zhang T. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis. J Matern Fetal Neonatal Med. 2022 Mar;35(5):861-870. doi: 10.1080/14767058.2020.1732342.China Antimicrobial Resistance Surveillance System. [Surveillance of bacterial resistance in children and newborns across China from 2014 to 2017]. Zhonghua Yi Xue Za Zhi. 2018 Oct 30;98(40):3279-3287. Chinese. doi: 10.3760/cma.j.issn.0376-2491.2018.40.013.China Antimicrobial Resistance Surveillance System. [Surveillance of bacterial resistance in children and newborns across China from 2014 to 2017]. Zhonghua Yi Xue Za Zhi. 2018 Oct 30;98(40):3279-3287. Chinese. doi: 10.3760/cma.j.issn.0376-2491.2018.40.013.Slocker-Barrio M., López-Herce-Cid J., Bustinza-Arriortúa A. et al. On Behalf Of The Pediatric-Envin-Helics Study Group. Increase in Incidence Rates and Risk Factors for Multidrug Resistant Bacteria in Septic Children: A Nationwide Spanish Cohort Study (2013-2019). Antibiotics (Basel). 2023 Nov 14;12(11):1626. doi: 10.3390/antibiotics12111626.Slocker-Barrio M., López-Herce-Cid J., Bustinza-Arriortúa A. et al. On Behalf Of The Pediatric-Envin-Helics Study Group. Increase in Incidence Rates and Risk Factors for Multidrug Resistant Bacteria in Septic Children: A Nationwide Spanish Cohort Study (2013-2019). Antibiotics (Basel). 2023 Nov 14;12(11):1626. doi: 10.3390/antibiotics12111626.Saporito L., Graziano G., Mescolo F., Amodio E. et al. Efficacy of a coordinated strategy for containment of multidrug-resistant Gram-negative bacteria carriage in a Neonatal Intensive Care Unit in the context of an active surveillance program. Antimicrob Resist Infect Control. 2021 Feb 4;10(1):30. doi: 10.1186/s13756-021-00902-1.Saporito L., Graziano G., Mescolo F., Amodio E. et al. Efficacy of a coordinated strategy for containment of multidrug-resistant Gram-negative bacteria carriage in a Neonatal Intensive Care Unit in the context of an active surveillance program. Antimicrob Resist Infect Control. 2021 Feb 4;10(1):30. doi: 10.1186/s13756-021-00902-1.Quirino A., Cicino C., Scarlata G.G.M. et al. Prevalence of Colonization with Multidrug-Resistant Bacteria: Results of a 5-Year Active Surveillance in Patients Attending a Teaching Hospital. Antibiotics (Basel). 2023 Oct 10;12(10):1525. doi: 10.3390/antibiotics12101525.Quirino A., Cicino C., Scarlata G.G.M. et al. Prevalence of Colonization with Multidrug-Resistant Bacteria: Results of a 5-Year Active Surveillance in Patients Attending a Teaching Hospital. Antibiotics (Basel). 2023 Oct 10;12(10):1525. doi: 10.3390/antibiotics12101525.Xu L., Sun X., Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16:18. doi: 10.1186/s12941-017-0191-3.Xu L., Sun X., Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16:18. doi: 10.1186/s12941-017-0191-3.Xiao R., Li Y., Liu X. et al. Antibiotic susceptibility of Escherichia coli isolated from neonates admitted to neonatal intensive care units across China from 2015 to 2020. Front Cell Infect Microbiol. 2023 May 22;13:1183736. doi: 10.3389/fcimb.2023.1183736.Xiao R., Li Y., Liu X. et al. Antibiotic susceptibility of Escherichia coli isolated from neonates admitted to neonatal intensive care units across China from 2015 to 2020. Front Cell Infect Microbiol. 2023 May 22;13:1183736. doi: 10.3389/fcimb.2023.1183736.Findlay J., Raro O.H.F., Poirel L., Nordmann P.; NARA Network. Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023. Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):551-557. doi: 10.1007/s10096-024-04752-8.Findlay J., Raro O.H.F., Poirel L., Nordmann P.; NARA Network. Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023. Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):551-557. doi: 10.1007/s10096-024-04752-8.Tenover F.C., Nicolau D.P., Gill C.M. Carbapenemase-producing Pseudomonas aeruginosa - an emerging challenge. Emerg Microbes Infect. 2022;11(1):811-814. doi: 10.1080/22221751.2022.2048972.Tenover F.C., Nicolau D.P., Gill C.M. Carbapenemase-producing Pseudomonas aeruginosa - an emerging challenge. Emerg Microbes Infect. 2022;11(1):811-814. doi: 10.1080/22221751.2022.2048972.Del Barrio-Tofiño E., López-Causapé C., Oliver A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.Int J Antimicrob Agents. 2020;56(6):106196. doi: 10.1016/j.ijantimicag.2020.106196.Del Barrio-Tofiño E., López-Causapé C., Oliver A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.Int J Antimicrob Agents. 2020;56(6):106196. doi: 10.1016/j.ijantimicag.2020.106196.Li H., Luo Y.F., Williams B.J., Blackwell T.S., Xie C.M. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.Int J Med Microbiol. 2012;302(2):63-68. doi: 10.1016/j.ijmm.2011.10.001.Li H., Luo Y.F., Williams B.J., Blackwell T.S., Xie C.M. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.Int J Med Microbiol. 2012;302(2):63-68. doi: 10.1016/j.ijmm.2011.10.001.Horcajada J.P., Montero M., Oliver A. et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4): e00031-e00019. doi: 10.1128/CMR.00031-19.Horcajada J.P., Montero M., Oliver A. et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4): e00031-e00019. doi: 10.1128/CMR.00031-19.Hujer A.M., Marshall S.H., Mack A.R. et al. Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam. mBio. 2023 Oct 27;14(6): e0111823. doi: 10.1128/mbio.01118-23.Hujer A.M., Marshall S.H., Mack A.R. et al. Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam. mBio. 2023 Oct 27;14(6): e0111823. doi: 10.1128/mbio.01118-23.Santerre Henriksen A., Jeannot K., Oliver A., Perry J.D., Pletz M.W., Stefani S., Morrissey I., Longshaw C.; ARTEMIS Study Investigators. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. Microbiol Spectr. 2024 Apr 2;12(4): e0383623. doi: 10.1128/spectrum.03836-23.Santerre Henriksen A., Jeannot K., Oliver A., Perry J.D., Pletz M.W., Stefani S., Morrissey I., Longshaw C.; ARTEMIS Study Investigators. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. Microbiol Spectr. 2024 Apr 2;12(4): e0383623. doi: 10.1128/spectrum.03836-23.

The authors declare that there are no conflicts of interest present.